

**Withdrawal of Bimatoprost Eye Drops 300mcg/ml (0.03%)**

**Recommendation**

Bimatoprost eye drops 300mcg/ml (0.03%) were discontinued on 1<sup>st</sup> July 2015. The manufacturers Allergan have confirmed that bimatoprost 100mcg/ml (0.01%) has been shown to be equivalent to the 300mcg/ml (0.03%) formulation in IOP lowering efficacy and demonstrated an improved tolerability profile in terms of hyperaemia severity, ocular adverse events and subsequent patient discontinuations.

The equipotency is achieved by an increased concentration of benzalkonium chloride in the 100mcg/ml formulation.

EKHFT ophthalmologists have confirmed that patients can be changed from 300mcg/ml to the 100mcg/ml eye drops.